Table 1.

Protocols in the literature

Study	Design	Mifepristone	Misoprostol	Success	Definition of success
Colleselli et al. [14]	Retrosp. N = 168	600 mg orally	400 mcg orally, followed by 400 mcg vaginally in 4 h intervals, max. 2400 mcg	61 %	Not standardized, Dependent on treating physician
Van den Berg et al [10]	Retrosp. N = 301	Group 1: 200 mg orally	Group 1: after 36 h 800 µg vaginally Group 2: 2 doses of 800 µg vaginally, time interval 24 h In both groups additional 800 µg vaginally if no bleeding or cramping after 24 h	Group 1: 67 % Group 2: 55 % (statistically significant)	Clinical signs, empty uterine cavity on ultrasound or hysteroscopy, absence of products of conception in histology
Barcelo et al. [27]	Retrosp. N = 946	–	2 doses of 600 µg or 800 µg vaginally, time interval 24 h	88/91 %	no gestational sac on ultrasound
Kollitz et al. [13]	Retrosp. N = 123	200 mg orally	After 24 h 800 µg vaginally, if indicated additional dose after 7 days	80/83 %	No presence of gestational sac and endometrial thickness <30 mm on ultrasound
Stockheim et al. [16]	Prosp. N = 115	Group 1: 600 mg orally	Group 1: after 48 h 800 µg orally Group 2: 2 doses of 800 µg orally, time interval 48 h	Group 1: 66 % Group 2: 74 %	No need for surgical intervention
Schreiber et al. [12]	Prosp. N = 30	200 mg orally	After 24 h 800 µg vaginally, if indicated additional dose after 7 days	90/93 %	Expulsion of gestational sac, no need for D&C
Zhang et al. [30]	Prosp. N = 652	–	800 µg vaginally, if indicated additional dose after 48 h	71/84 %	no need for surgical intervention within 30 days after initial treatment
Grønlund et al [15]	Prosp. N = 176	Group 1: 600 mg orally	400 µg vaginally, if no bleeding after 2 h à 200 µg additionally (group 1: 48 h after mifepristone)	Group 1: 4 % Group 2: 71 %	No need for surgical evacuation after medical treatment

Retrosp. retrospective, prosp. prospective